KLRA
Kailera Therapeutics, Inc. Common Stock
NASDAQ: KLRA · HEALTHCARE · BIOTECHNOLOGY
$25.15
+0.60% today
Updated 2026-05-01
Market cap
$3.21B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.26
Dividend yield
—
52W range
$16 – $28
Volume
1.8M
Kailera Therapeutics, Inc. Common Stock (KLRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2025 |
|---|---|
| Revenue | $0.00 |
| Revenue growth (YoY) | — |
| Cost of revenue | — |
| Gross profit | — |
| Gross margin | — |
| R&D | $109.11M |
| SG&A | $49.23M |
| Operating income | $-158.34M |
| Operating margin | — |
| EBITDA | — |
| EBITDA margin | — |
| EBIT | — |
| Interest expense | — |
| Income tax | — |
| Effective tax rate | 0.0% |
| Net income | $-148.96M |
| Net income growth (YoY) | — |
| Profit margin | — |